| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST25: Lumasiran for treating primary hyperoxaluria type 1 |
|
Medicine details |
|
| Medicine name | lumasiran (Oxlumo®) |
| Formulation | subcutaneous injection |
| Reference number | 4080 |
| Indication | Treatment of primary hyperoxaluria (type 1) in all age groups |
| Company | Alnylam Pharmaceuticals Inc |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/02/2021 |
| NICE guidance | |